These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8618956)

  • 21. Azimilide dihydrochloride.
    Carlson M
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):387-91. PubMed ID: 15889966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
    Camm AJ; Pratt CM; Schwartz PJ; Al-Khalidi HR; Spyt MJ; Holroyde MJ; Karam R; Sonnenblick EH; Brum JM;
    Circulation; 2004 Mar; 109(8):990-6. PubMed ID: 14967728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of azimilide with neurohumoral and channel receptors.
    Brooks RR; Pong SF; Izzo NJ; Moorehead TJ; Gopalakrishnan M; Triggle DJ
    Biochem Pharmacol; 2001 Oct; 62(7):883-92. PubMed ID: 11543723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of isoproterenol on the class III effect of azimilide in humans.
    Dorian P; Dunnmon P; Elstun L; Newman D
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):211-7. PubMed ID: 12490966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azimilide. NE 10064, Stedicor.
    Drugs R D; 1999 Apr; 1(4):297-300. PubMed ID: 10566048
    [No Abstract]   [Full Text] [Related]  

  • 26. Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit.
    Brooks RR; Drexler AP; Maynard AE; Al-Khalidi H; Kostreva DR
    Proc Soc Exp Biol Med; 2000 Feb; 223(2):183-9. PubMed ID: 10654622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
    Pratt CM; Al-Khalidi HR; Brum JM; Holroyde MJ; Schwartz PJ; Marcello SR; Borggrefe M; Dorian P; Camm AJ;
    J Am Coll Cardiol; 2006 Aug; 48(3):471-7. PubMed ID: 16875971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.
    Van Opstal JM; Leunissen JD; Wellens HJ; Vos MA
    Eur J Pharmacol; 2001 Jan; 412(1):67-76. PubMed ID: 11166738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Azimilide: Search for an effective and well-tolerated anti-arrhythmia agent].
    Z Kardiol; 1999 Oct; 88(10 Suppl):1-2. PubMed ID: 10586493
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibitory effect of azimilide on Na+/Ca2+ exchange current in guinea-pig cardiac myocytes.
    Watanabe Y; Kimura J
    J Pharmacol Sci; 2010; 114(1):111-4. PubMed ID: 20710119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation.
    Connolly SJ; Schnell DJ; Page RL; Wilkinson WE; Marcello SR; Pritchett EL
    Am J Cardiol; 2001 Nov; 88(9):974-9. PubMed ID: 11703992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: considerations on the mechanism of reverse rate-dependent action potential prolongation.
    Groh WJ; Gibson KJ; Maylie JG
    J Cardiovasc Electrophysiol; 1997 May; 8(5):529-36. PubMed ID: 9160229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiarrhythmic effect of the selective I1-imidazoline receptor modulator moxonidine on ouabain-induced cardiac arrhythmia in guinea pigs.
    Mest HJ; Thomsen P; Raap A
    Ann N Y Acad Sci; 1995 Jul; 763():620-33. PubMed ID: 7677382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
    Pritchett EL; Schulte MC; Schnell D; Marcello SR; Wilkinson WE; Page RL; Connolly SJ;
    J Clin Pharmacol; 2002 Apr; 42(4):388-94. PubMed ID: 11936563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
    Pratt CM; Singh SN; Al-Khalidi HR; Brum JM; Holroyde MJ; Marcello SR; Schwartz PJ; Camm AJ;
    J Am Coll Cardiol; 2004 Apr; 43(7):1211-6. PubMed ID: 15063432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of dantrolene sodium in rodent models of cardiac arrhythmia.
    Brooks RR; Carpenter JF; Jones SM; Gregory CM
    Eur J Pharmacol; 1989 May; 164(3):521-30. PubMed ID: 2767123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action.
    Busch AE; Eigenberger B; Jurkiewicz NK; Salata JJ; Pica A; Suessbrich H; Lang F
    Br J Pharmacol; 1998 Jan; 123(1):23-30. PubMed ID: 9484850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.
    Pritchett EL; Kowey P; Connolly S; Page RL; Kerr C; Wilkinson WE;
    Am Heart J; 2006 May; 151(5):1043-9. PubMed ID: 16644334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of azimilide and dofetilide in the dog right atrial enlargement model of atrial flutter.
    Restivo M; Hegazy M; El-Hamami M; Yin H; Caref EB; Assadi MA; Brooks RR; El-Sherif N
    J Cardiovasc Electrophysiol; 2001 Sep; 12(9):1018-24. PubMed ID: 11573691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.